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We have identified the protein biomarkers observed in the matrix-assisted laser desorption/ionization
time-of-flight mass spectra (MALDI-TOF-MS) of cell lysates of five strains of Campylobacter upsaliensis
and one strain of C. helveticus by “bottom-up” proteomic techniques. Only one C. upsaliensis strain
had previously been genomically sequenced. The significant findings are as follows: (1) The protein
biomarkers identified were: 10 kD chaperonin, protein of unknown function (DUF465), phnA protein,
probable periplasmic protein, D-methionine-binding lipoprotein MetQ, cytochrome c family protein,
DNA-binding protein HU, thioredoxin, asparigenase family protein, helix-turn-helix domain protein, as
well as several ribosomal and conserved hypothetical proteins. (2) Amino acid substitutions in protein
biomarkers across species and strains account for variations in biomarker ion mass-to-charge (m/z).
(3) The most common post-translational modifications (PTMs) identified were cleavage of N-terminal
methionine and N-terminal signal peptides. The rule that predicts N-terminal methionine cleavage,
based on the penultimate residue, does not appear to apply to C. upsaliensis proteins when the
penultimate residue is threonine. (4) It was discovered that some protein biomarker genes of the
genomically sequenced C. upsaliensis strain were found to have nucleotide sequences with GTG or
TTG “start” codons that were not the actual start codon (ATG) of the protein based on proteomic
analysis. (5) Proteomic identification of the protein biomarkers of the non-genomically sequenced C.
upsaliensis and C. helveticus strains involved identification of homologous protein amino acid sequences
to that of the sequenced strain. Interestingly, some protein sequence regions that were not completely
homologous to the sequenced strain, due to amino acid substitutions, were found to have homologous
sequence regions from more phyogenetically distant species/strains, e.g., C. jejuni. Exploiting this partial
homology of more distant species/strains, it was possible to construct a “composite” amino acid
sequence using multiple non-overlapping sequence regions from both phylogenetically proximate and
distant strains. The new composite sequence was confirmed by both MS and MS/MS data. Thus, it
was possible in some cases to determine the amino acid sequence of an unknown protein biomarker
from a genomically non-sequenced bacterial strain without the necessity of either genetically sequencing
the biomarker gene or resorting to de novo MS/MS analysis of the full protein sequence.
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Introduction
Emerging technologies to detect and identify foodborne
microorganisms is an active area of analytical science with
impact on food safety and public health. A number of analytical
approaches are possible, however mass spectrometry-based
techniques have gained favor due to their speed, sensitivity,
and specificity. The ionization techniques most commonly used
in mass spectrometry for protein analysis are electrospray
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ionization (ESI)1 and matrix-assisted laser desorption/ionization (MALDI).2-3 Given the unique chemical and physical
processes involved in ionization by ESI and MALDI, selection
of the ionization technique is often dictated by the complexity
and purity of the type of sample to be analyzed. The ionization
technique selected will often determine the type of mass
analyzer to be used and the speed of sample analysis. MALDI
is traditionally associated with high throughput analysis whereas
ESI has been primarily associated with analysis coupled to
liquid chromatography (LC), which increases the time of
analysis.
Williams, Musser, and co-workers have demonstrated the
feasibility of generating a unique protein molecular weight
Journal of Proteome Research 2007, 6, 2539-2549
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(MW) “fingerprint” or profile for bacterial micro-organisms
using LC/ESI-MS.4-6 As each protein generates its own charge
state envelope due to the multiple charging nature of ESI, the
LC/ESI-MS data must be deconvoluted in time intervals
corresponding to the elution of specific proteins. The deconvoluted data is then compiled to provide a unique profile of
protein MWs (150+).4-5 Differences in protein MW profiles
among closely related strains (pathogenic versus nonpathogenic) may lead to identification of proteins involved (or at least
correlated) to virulence factors. The only significant disadvantage of this approach is the time required for chromatographic
separation. To maximize the number of proteins detected (and
thus increase the probability of generating a unique protein
profile), it is advantageous to maximize chromatographic
resolution in order to reduce the possibility of competitive
ionization of coeluting proteins. Another challenge is that the
dynamic range of protein concentrations in bacteria is several
orders-of-magnitude. Significant, but low abundant, proteins
may not be detected due to coelution with more abundant
proteins. In consequence, good chromatographic resolution is
critical but may lengthen the time of analysis.
Another approach that is gaining in popularity for microorganism identification is MALDI time-of-flight mass spectrometry (TOF-MS).7-19 This technique involves analysis of intact
microorganisms (or cell lyates) by detection of high copy
primarily cytosolic proteins. As MALDI generates primarily
singly charged protein ions, spectral complexity is not a
significant problem and no data deconvolution is required.
However, the number proteins detected is typically in the range
of 20-50, and because the number of open reading frames in
a microorganism genome is typically 1500-2500, the number
of proteins detected by MALDI-TOF-MS is relatively small.
However, even with the relatively small number of proteins
detected, MALDI-TOF-MS has demonstrated its utility to
differentiate bacterial microorganisms by genus, species, subspecies, and strain.7-22 In addition, the advantages of this
approach are minimal sample preparation (beyond microorganism culturing) and very rapid MS analysis time as no
chromatography is involved. MALDI-TOF-MS data are most
commonly analyzed by pattern recognition algorithms,23-24
although increasingly bioinformatics approaches to data analysis are also gaining favor.25-28
Our group has extensively analyzed foodborne bacterial
microorganisms using MALDI-TOF-MS and, in particular,
Campylobacter20-22 which is responsible for 2.4 million incidents of foodborne illness each year in the US.29 We have
demonstrated the ability to speciate20,21 and even sub-speciate22
Campylobacter using this technique. In addition, we have
systematically extracted and identified by “bottom-up” proteomics techniques the proteins responsible for generating the
relatively unique protein profile. In the process, we have
identified the factors that contribute to making a MS spectrum
unique to a particular microorganism.21,22
In the current study, we have identified C. upsaliensis and
C. helveticus protein biomarkers that are prominently observed
in the MALDI-TOF-MS spectra of bacterial cell lysates. Protein
biomarkers of five strains of C. upsaliensis were selected for
extraction and identification: RM3195, RM2092, RM4249,
RM3776, and RM4245. In addition, one strain of C. helveticus
(a closely related species to C. upsaliensis) was also selected
for extraction and identification: RM3807. Only the genome
of C. upsaliensis strain RM3195 has been fully sequenced and
annotated,30 however the other strains in this study have been
2540
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speciated by extended multi-locus sequence typing.31 We also
demonstrate the ability to determine the full amino acid
sequence of a protein biomarker from a genomically nonsequenced bacterial strain by combining proteomic identifications from multiple non-overlapping identifications. This “composite” sequence is then confirmed by MS and MS/MS data.

Materials and Methods
A detailed description of the protocol for protein biomarker
detection,extraction,andidentificationwasreportedpreviously.20-22
The following is an abbreviated description of the experimental
procedures employed. Warning: Campylobacter is a Biosafety
Level 2 human pathogen. All appropriate precautions were
taken when handling this pathogen. Campylobacter upsaliensis
and C. helveticus strains were grown as previously described20-22
on nonselective growth media at 37-42 °C for 24-48 h after
which cells were harvested and analyzed by MALDI-TOF-MS
analysis or prepared for protein extraction and analysis.
Campylobacter cells were lysed and their proteins extracted
using a solution of 2:1 water/acetonitrile, 0.1% trifluoroacetic
acid. The cells were lysed by bead-beating in the extraction
solution for 60 s. Centrifugation pelleted cellular membrane
and other insoluble material. The supernatant was analyzed
by MALDI-TOF-MS analysis and separated by high performance liquid chromatography (HP Series II 1090, Palo Alto, CA).
HPLC fractions were analyzed by MALDI-TOF-MS. Protein
biomarkers in HPLC fractions that were also detected in the
original MALDI-TOF-MS analysis of cell lysate were, after
centrifugal evaporation, separated by 1-D SDS-PAGE. Gels were
fluorescently stained, imaged, and prominent gel bands excised.
The gel bands were subjected to in-gel tryptic digestion with
an automated protein digester.
MALDI-TOF-MS of cell lysates and HPLC fractions has been
described in detail elsewhere.21,22 Briefly, a sub-saturated
solution of trans-4-hydroxy-3-methoxy-cinnamic acid (ferulic
acid) was prepared in 2:1 water/acetonitrile with 0.1% TFA. The
matrix was spotted onto a square stainless-steel target plate
with 7 × 7 array of deposition sites. After drying at room
temperature, the cell lysate supernatant (or the HPLC eluent)
was spotted on top of the dried matrix spot. After external
calibration of the instrument, the sample was analyzed on a
Reflex II MALDI-TOF mass spectrometer (Bruker Daltonics,
Billerica, MS) in reflectron-mode at an ion acceleration voltage
of 20 kV resulting in a mass accuracy of (10 Da. Instrument
resolution was 800-1200 fwhm. Data was processed with the
software provided with the instrument.
A more accurate molecular weight (MW) measurement was
made of a protein biomarker by high-resolution electrospray
ionization mass spectrometry (HR-ESI-MS) of the HPLC fraction containing the protein biomarker.21-22 A quadrupole/timeof-flight (Qq-reflecton-TOF) mass spectrometer (Q-STAR Pulsar
I, MDS Sciex/ABI, Toronto, Canada) was utilized for such
measurements. The measured MW of a protein biomarker was
determined by deconvolution of the charge state envelope of
the HR-ESI-MS spectrum using a Bayesian protein reconstruct
algorithm available with the commercial software of the
instrument (Analyst 1.2). Three separate HR-ESI-MS measurements were made of each biomarker. The reflectron-TOF of
the Qq-TOF was calibrated externally with the peptide glufibrogen prior to each measurement.21-22 An average and standard
deviation was then calculated from these three measurements.
The TOF resolution was typically FWHM 7000-9000. A discrepancy greater than (1 Da between the predicted MW and
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Table 1. Sources and Locations of Five Strains of C.
upsaliensis and One Strain of C. helveticus
strain

synonym

RM3195 ATCC BAA-1059
RM2092
RM4249
RM3776
RM4245
RM3807

species

source

location

C. upsaliensis
"
"
"
"
C. helveticus

human
human
human
human
human
feline

South Africa
unknown
Belgium
South Africa
Belgium
USA (CA)

HR-ESI-MS MW suggested the presence of an unidentified
PTM or amino acid substitution.
Products of in-gel digestion were analyzed by nanoflow
HPLC system (LC Packings/Dionex , Sunnyvale, CA) with a
1000-to-1 split interfaced to the hybrid Qq-TOF instrument.
Samples were preconcentrated with a C18 “trap” column prior
to being chromatographically separated on the C18 monomeric
analytical column. Tryptic peptides of digested proteins were
ionized by ESI, detected by a MS survey scan, mass selected
by the first quadrupole, fragmented by collision-induced dissociation in the second quadrupole (with nitrogen as the target
gas) and the fragment ions analyzed by the TOF mass analyzer.
Data were acquired using the data dependent scanning of the
instrument software.
The MS/MS data files generated by the instrument software
were processed to MGF files using a WIFF-to-DTA batch
converter.32 The DTA files containing MS/MS data were then
used to search against a flat file containing amino acid
sequences of all eubacterial proteins encoded in the National
Center for Biotechnology Information nonredundant database
(NCBI nr). An in-house version of MASCOT33 and Global
Proteome Machine34 search engines were used for database
searching. De novo sequencing was accomplished using PEAKS
software (Bioinformatics Solutions Inc., Version 4.0). The
predicted average MW of a protein was calculated from its
amino acid sequence using GPMAW software (Lighthouse data,
Version 7.0).

Results
C. upsaliensis and C. helveticus Strains. Table 1 shows the
sources and locations of the five strains of C. upsaliensis
(RM3195, RM2092, RM4249, RM3776, RM4245) and one strain
of C. helveticus (RM3807) analyzed in this study. Only C.
upsaliensis strain RM3195 has been fully genomically sequenced.30 C. upsaliensis strains RM2092, RM4249, RM3776,
and RM4245 and C. helveticus strain RM3807 were previously
characterized by extended multilocus sequence typing (MLST).31
MALDI-TOF-MS of Campylobacter. Figure 1 shows a typical
MALDI-TOF-MS spectrum of a cell lysate extract of Campylobacter, specifically of C. helveticus strain RM3807. Numerous
protein biomarker m/z ion peaks are observed. MALDI-TOFMS of cell lysates of C. upsaliensis strains RM3195, RM2092,
RM4249, RM3776, and RM4245 have many more ion peaks (m/
z) that are common to each other than are common to the C.
helveticus strain RM3807 (Tables 2 and 3). Amino acid substitutions caused by non-synonymous mutations of the protein
biomarker gene are responsible for “shifts” in ion peaks (m/z)
across species and strains.21-22 The phylogenetic distance
between species and strains is reflected in the number of
biomarkers that undergo a mass shift.
Previously, the protein biomarker ion at m/z 10191 (m/z
5095, +2) in Figure 1, was detected, extracted and proteomically
identified to be the DNA-binding protein HU.21 The HU protein

biomarker for strains C. upsaliensis strains RM3195, RM2092,
RM3776 and RM4245 were also detected, extracted, and identified by proteomic techniques.21 Proteomic identification relied
upon DNA sequencing of the HU gene (hup) of a particular
strain. In the case of C. helveticus strain RM3807, it was not
possible to sequence the hup gene because the primers used
for C. upsaliensis did not amplify for the C. helveticus strain
presumably because the flanking genes were different. However, there was enough conserved homology between C.
upsaliensis and C. helveticus HU such that it was possible to
identify the protein biomarker at m/z 10191 as being HU
without determining its full sequence. Variations in HU MW
among these various strains were the result of the previously
mentioned amino acid substitutions caused by nonsynonymous mutations of hup.
Protein Biomarker Extraction and Identification. Detection,
extraction, and proteomic identification was performed on the
other protein biomarkers observed in the MALDI-TOF-MS
spectra of RM3195, RM2092, RM4249, RM3776, RM4245, and
RM3807. Table 2 and 3 summarizes the protein biomarkers that
were identified definitively by proteomic techniques as well as
those that could only be assigned tentatively based on limited
MS or MS/MS data. Tentative assignments were assigned based
on the proximity of the m/z of the biomarker ion in one strain
to the m/z of a biomarker ion in another strain that had been
identified successfully by proteomics techniques. Mass shifts
of (15-60 Da between biomarkers from different strains/
species were assumed to be the result of amino acid substitutions. Including HU, a total of 17 protein biomarkers were
identified (although they were not always detected and identified in all strains). They are: DNA-binding protein HU, 50S
ribosomal L7/L12, 50S ribosomal L24, protein of unknown
function DUF465, asparaginase family protein, 30S ribosomal
S16, cytochrome c family protein, hypothetical protein Cup
0937, probable periplasmic protein, 50S ribosomal L29, 10 kD
chaperonin, thioredoxin, phnA protein, D-methionine-binding
lipoprotein MetQ, 50S ribosomal L27, conserved hypothetical
protein, and helix-turn-helix domain protein. Over half of the
biomarkers were post-translationally modified. Two of the
biomarkers have genes with “start” codons in the nucleotide
sequence of strain RM3195 that were incorrect based on
proteomic analysis. Proteomic analysis was performed with
both MASCOT and GPM search engines (both scores are
provided in Tables 2 and 3).
As mentioned previously, only strain RM3195 has been fully
genomically sequenced. In consequence, proteomic identification of the protein biomarkers of the other strains in this study
were identified based on their full or partial sequence homology
to the protein biomarker sequences of RM3195 (or other
genomically sequenced Campylobacter). In addition to biomarker identification by analysis of MS/MS of tryptic peptides,
it was also possible, in some cases, to identify (or confirm) the
full amino acid sequence of a protein biomarker by combining
multiple identifications (not only the highest scoring identification) to generate a “composite” sequence of the biomarker. A
HR-ESI-MS measurement of the biomarker MW was used to
confirm the correctness of the composite sequence. The
composite sequence was also confirmed by MS/MS data.
Composite Sequence Proteomic Analysis (CSPA) of Bacterial Protein Biomarkers. Table 4 shows the process of identification used to determine the amino acid sequence of a
protein biomarker (phnA protein) of C. upsaliensis strain
RM4245 whose gene is not sequenced. MASCOT and GPM
Journal of Proteome Research • Vol. 6, No. 7, 2007 2541
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Figure 1. MALDI-TOF-MS of cell lysate of C. helveticus strain RM3807.

contains sequence coverage of a region of the protein that is
not covered by higher scoring identification. Combining the
sequence coverage of both the highest and lower scoring
identifications results in a composite sequence. The composite
sequence also includes protein sequence regions not confirmed
by either identification but which are (in this example) common

analysis of its MS/MS datafile return both a high scoring
identification (phnA protein of C. upsaliensis strain RM3195)
and a lower scoring identification (phnA-like protein of C. jejuni
jejuni NCTC 11168). As RM4245 is an C. upsaliensis it is not
surprising that the highest scoring identification is another C.
upsaliensis strain. Interestingly, the lower scoring identification

Table 2. Protein Biomarkers of C. upsaliensis Strains RM3195, RM2092, and RM4249 That Were Detected, Extracted, and/or
Identified by Proteomic Techniquesa
Protein Biomarkers (* signifies presence of a PTM. ** signifies an error in the "start" codon of the biomarker gene.)

50S*
50S*
L7/L12 L24

DUF Aspara465** ginase*

10272

12856

8450

10270.821
( 0.3

12855.8
( 0.2

10270.921

12986.8
12855.6*

-155.921
10171

-68.3
884
12886

10171.721
( 0.1

12887.7
( 0.1

HU
RM 3195

RM 2092

RM 4249

MALDI-TOF
(m/z)20
HR-ESI-MS
Ave MW
(Da)
Predicted
Ave MW
(Da)
GPM log(e)
Mascot
MALDI-TOF
(m/z)20
HR-ESI-MS
Ave MW
(Da)
Predicted
Ave MW
(Da)
GPM log(e)
Mascot
MALDI-TOF
(m/z)
HR-ESI-MS
Ave MW
(Da)
Predicted
Ave MW
(Da)
GPM log(e)
Mascot

10171.821

7924

14207

8449.5
( 0.2
8053.8
(-SH)
7922.6

7923

*11664.5
8449.6**
-26.1
167
8422

36333.9
(-SH)
14205.1*

14190

50S
L29

Chaper- ThioreD-met 50S*
onin** doxin* phnA* MetQ* L27

CHP

Helix
TurnHelix

10022

9771

9504

13647

7063

9301

11139

8712.0
( 0.1

9501.5
( 0.0

13648.1
( 0.3

7061.7
( 0.1

9299.8
( 0.1

11137.8
( 0.2

7350.1
( 0.3

13202
(+2)
26413.1
( 0.7

8712.2

10869.8
(3 -SH)
9504.8*

15463.7
13647.4*

7061.6

10656.6
9299.8**

7481.7
7350.5*

28568.0
26411.3*

-19.6
158
8725

-16.1
225
9503

-70.6
496

-26.1
452
7061

-72.1
553
9317

11268.0
(S-S,
-SH)
11137.8*
-43.7
537
11137

-6.2
101

-81.8
951

7061.6

9317.9
(Comp.)

13841.2

13953

10869.8
(3 -SH)
9504.8*

-97.0
957
12892

7926

8425

14211

10171.5
( 0.2

12887.6
( 0.3

7922.6
( 0.1

8421.4
( 0.1

14204.6
( 0.2

-43.1
565

8053.8
(-SH)
7922.6*
-17.7
305

-13.4
119

36333.9
(-SH)
14205.1*
-87.1
717

-101.0
472

HP Cup
Peri0937
plasmic*

8712

8053.8
(-SH)
7922.6*

10171.8

Cyto-c*

10026.9
( 0.3
9284.7
9153.7*

10026.5

9768.7

10042

9787

10004
10034

9797

13955.3
( 0.1

10175

-91.521

30S
S16

7064

-44.6
(Comp.)
9321

11268.0
(S-S,
-SH)
11137.8*
-34.2
399
11170

7061.2
( 0.2

9318.7
( 0.7

11165.8
( 0.2

7061.6

9317.9
(Comp.)

11165.8

-1.3
44

-11.1
(Comp.)

-54.2

-32.8
278
8729

9506

10869.8
(3 -SH)
9504.8*

7353

13185
(+2)

a
Biomarkers detected and/or extracted from a strain but not identified by proteomics techniques were nonetheless assigned tentatively if the biomarker
was identified by proteomics techniques in another strain. Tentative assignments are in italics; the oxidation state of protein cysteines are indicated by S-S
or -SH (or both) and incorporated into the MW calculation. Biomarker amino acid sequences and MWs determined by composite sequence analysis and/or
de novo sequencing are indicated.
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Table 3. Protein Biomarkers of C. upsaliensis Strains RM3776, RM4245 and C. helveticus Strain RM3807 That Were Detected,
Extracted, and/or Identified by Proteomic Techniques
Protein Biomarkers (* signifies presence of a PTM. ** signifies an error in the "start" codon of the biomarker gene.)

HU
RM 3776

RM 4245

MALDI-TOF
(m/z)20
HR-ESI-MS
Ave MW
(Da)
Predicted
Ave MW
(Da)
GPM log(e)
Mascot
MALDI-TOF
(m/z)20
HR-ESI-MS
Ave MW
(Da)
Predicted
Ave MW
(Da)
GPM log(e)
Mascot

RM 3807

MALDI-TOF
(m/z)
HR-ESI-MS
Ave MW (Da)
Predicted
Ave MW
(Da)
GPM log(e)
Mascot

50S* 50S*
L7/L12 L24

DUF Aspara- 30S
HP Cup
Peri50S Chaper- Thiore
D-met
465** ginase* S16 Cyto-c* 0937 plasmic* L29 onin** doxin* phnA* MetQ*

10197

12852

8449

10198.7 21
( 0.1

12855.8
( 0.3

8449.6
( 0.2

10198.9 21

12986.8
12855.6*

11664.5
8449.6**

-257.4 21

-99.8
1241

-56.3
389

10229

12857

10226.8 21
( 0.2

12855.8
( 0.1

10226.9 21

12986.8
12855.6*

-264.8 21

-112.5
1225

10191 21

13276

10186.9 21
( 0.3
10185.9
(Comp.&
de novo)

13270.9
( 0.4

-186.4
(Comp.&
de novo)

-139.7
989

7924

8053.8
(-SH)
7922.6*

8451

11664.5
8449.6**

8454

14200

36333.9
(-SH)
14205.1*

14209

8712

9502

8712.0
( 0.2

9501.7
( 0.1

8712.2

15463.7
13647.4*

-15.1
440

10869.8
(3 -SH)
9504.8*
-29.8
318

8759

9506

13663

36333.9
(-SH)
14205.1*

14180

10869.8
(3 -SH)
9504.8

8741

9507

14175.1
( 0.4
11664.5
8449.6**

10869.8
(3 -SH)
9504.8*
-26.0
127

13646

7060

9298

11135

7061.3
( 0.1

9299.8
( 0.4

11137.9
( 0.3

7061.6

10656.6
9299.8**

-14.3
349

-85.0
618

11268.0
(S-S,-SH)
11137.8*
-40.7
531

7063

9302

11139

7325

9299.6
( 0.3

11137.6
( 0.3

7323.6
( 0.1

10656.6
9299.8**

11268.0
(S-S,-SH)
11137.8*

7454.7
7323.5*
(Comp.)

-88.3
678

-84.7
680

-30.0
(Comp.)

7064

9365

11179

7376

7061.3
( 0.2
7061.6

9361.3
( 0.6
9361.9
(Comp.&
de novo)

11177.0
( 0.4
11176.8
(Comp. &
de novo)

-41.6
469

-61.0
(Comp.&
de novo)

-68.3
(Comp.&
de novo)

7061.6

CHP

Helix
TurnHelix

9168

10053

9770

9181.3
( 0.0
(Met Ox)

10051.1
( 0.3

50S*
L27

13205
(+2)

28568.0
26411.3*

13185
(+2)

9768.7

-64.2
398

-54.2
590

154

a
Biomarkers detected and/or extracted from a strain but not identified by proteomics techniques were nonetheless assigned tentatively if the biomarker
was identified by proteomics techniques in another strain. Tentative assignments are in italics. The oxidation state of protein cysteines are indicated by S-S
or -SH (or both) and incorporated into the MW calculation. Biomarker amino acid sequences and MWs determined by composite sequence analysis and/or
de novo sequencing are indicated.

to both sequences. The MW of this composite sequence is then
calculated and compared to the HR-ESI-MS MW of the protein
biomarker. Excellent agreement was obtained between the
predicted MW and HR-ESI-MS MW when N-terminal methionine cleavage is included. As the penultimate residue of
this protein is alanine, post-translational removal of methionine
is consistent with the bacterial rule that predicts N-terminal
methione cleavage.26,35-37 Finally, the composite sequence is
included into the GPM database and the MS/MS datafile is
reanalyzed. The result is an improved identification score and
greater sequence coverage of the protein biomarker. MS and
MS/MS confirmation of the composite sequence leaves little
doubt as to its correctness. Thus, it is possible, in some cases,
to identify the full amino acid sequence of a protein biomarker
of a genomically nonsequenced bacterial strain using CSPA. A
brief comment about terminology. The term “consensus sequence” is commonly used in genomics and bioinformatics to
refer to the process by which a number of different sequences
(usually DNA sequences) are aligned, and the common elements are highlighted or selected. In contrast, the process of
constructing a composite sequence is not simply combining
“common” elements from differing amino acid sequences
(although this may also occur). A composite sequence specifically includes non-overlapping sequence regions that are not
common to all sequences but which are determined to be
correct based on MS/MS data and database searching. Thus,
a composite sequence is not the same as a “consensus
sequence” as the processes involved are actually different.
A more complex example using CSPA is shown in Table 5
for the identification of 10 kD chaperonin of C. helveticus strain
RM3807. MASCOT and GPM analysis of its MS/MS datafile
returned both a high scoring identification (10 kD chaperonin
of C. upsaliensis strain RM3195) and a lower scoring identification (10 kD chaperonin of C. jejuni jejuni strain RM1221).
Interestingly, the high scoring identification also revealed a

problem with amino acid sequence of 10 kD chaperonin of
RM3195 in the NCBI database. Specifically, the N-terminus of
the protein is not confirmed by proteomic analysis. In addition,
the “start” codon of the chaperonin gene (groES) for RM3195
is “GTG” a possible (although not typical) start codon of a
bacterial gene sequence. In any case, combining the high and
low scoring identifications results in a composite sequence
covering over 75% of the biomarker sequence. However, there
still remain sequence regions unconfirmed by MS/MS that are
common (and not common) to both identifications. Calculating
the predicted MW using either of these possibilities results in
a value that is not consistent with the HR-ESI-MS MW of the
biomarker. De novo analysis of the MS/MS data and focusing
primarily on identifying those sequence regions not confirmed
by database identifications resulted in identification of the
sequence 46EVSDVTSGDKILFAK (and another sequence 10VLVK). The 46EVS... de novo sequence although more similar
to the C. upsaliensis sequence than to C. jejuni sequence is
still different by three residues (boxed). Addition of this partial
sequence to the composite sequence results in a full sequence
with a predicted MW that is in good agreement with the HRESI-MS MW of the biomarker. Finally, confirmation of this
combined composite and de novo sequence by GPM resulted
in a significantly higher score and almost complete confirmation of the entire biomarker sequence. Protein biomarker
sequences determined by composite sequencing or composite
and de novo sequencing are indicated in Tables 2 and 3.
Post-Translational Modifications of C. upsaliensis and C.
helveticus Protein Biomarkers. The post-translational modification (PTM) most commonly detected and identified was
N-terminal methionine (Nt-Met) cleavage. The presence of this
PTM was confirmed by MS and/or MS/MS for the following
proteins: thioredoxin, phnA protein, and the 50S ribosomal
proteins L7/L12, L24, and L27. The penultimate residue of these
proteins is either alanine or glycine. The rule that governs NtJournal of Proteome Research • Vol. 6, No. 7, 2007 2543
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Table 4. Proteomic Analysis of the phnA Protein from C. upsaliensis Strain RM4245a

a
Boxed residues highlight amino acid variations between high and low scoring identifications (C. upsaliensis strain RM3195 and C. jejuni jejuni strain
NCTC 11168, respectively) using both MASCOT and GPM analysis. Red indicates the sequence was confirmed by MS/MS. The composite sequence combines
non-overlapping sequence regions of both the highest and lower scoring identifications that were confirmed by MS/MS. The composite sequence also includes
unconfirmed sequence regions common to both strains.

Met cleavage for bacterial proteins, as determined by the
penultimate residue, predicts Nt-Met removal when the penultimate residue is alanine or glycine.26,35-37 Thus, rule and
observation are consistent. The rule also predicts Nt-Met
removal when the penultimate residue is threonine, however
it was observed that both the DNA-binding protein HU and
the 30S ribosomal S16 protein retain their Nt-Met even though
threonine is the penultimate residue. Our previously reported
results have also found this to be the case for C. jejuni, C. coli,
C. lari, and C. concisus strains.21,22 Previously, we conjectured
that the methionine aminopeptidase responsible for Nt-Met
2544
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removal has a somewhat different activity in Campylobacter
species compared to other bacteria.22 Differences in methionine
aminopeptidase activity among different bacteria are due
presumably to differences in the primary sequence of the
enzyme. For example, the primary sequence of methionine
aminopeptidase for E. coli O157:H7 strain Sakai is significantly
different from the primary sequence of C. upsaliensis strain
RM3195.
Other PTMs were also detected in four protein biomarkers:
asparaginase family protein, probable periplasmic protein,
cytochrome c family protein, and D-methionine-binding lipo-
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Table 5. Proteomic Analysis of the 10 kD Chaperonin from C. helveticus Strain RM3807

a
Boxed residues highlight amino acid variations between highest and lower scoring identifications (C. upsaliensis strain RM3195 and C. jejuni jejuni strain
RM1221, respectively) using both MASCOT and GPM analysis. Red indicates the sequence was confirmed by MS/MS. The composite sequence combines
sequence regions of both high and low scoring identifications that were confirmed by MS/MS as well as unconfirmed sequence of both strains. These unconfirmed
sequence regions in the composite sequence did not correspond to HR-ESI-MS MW of the biomarker. In consequence, de novo sequencing (in blue) was
employed to fill in “gaps” in the sequence.

protein MetQ. These proteins were found to have undergone
post-translational removal of a signal peptide or cleavage of
the polypeptide chain as shown in Table 6. In the case of
cytochrome c family protein, in addition to removal of a 19residue signal peptide from the N-terminus, there is also
covalent attachment of a heme group to the polypeptide via
two thioether bonds with two cysteine residues. This protein
biomarker and its PTMs were also detected in C. jejuni strains.22
A ∼ 3 Da discrepancy between the measured and predicted
protein MW is due presumably to another PTM. A similar mass
discrepancy was observed in C. jejuni cytochrome c-553 except
there the mass discrepancy was ∼ 2 Da.22 In the case of the
asparaginase family protein, the protein biomarker detected,
extracted, and identified may (or may not) be the functional

protein. The protein appears to be severed in half with only
the C-terminal polypeptide being detected (but detected
consistently) in several strains.
“Start” Codon Discrepancies in the Protein Biomarker
Genes of C. upsaliensis Strain RM3195. Proteomic analysis of
two protein biomarkers: 10 kD chaperonin and domain of
unknown function protein (DUF465), revealed that the actual
N-terminus of the protein was not consistent with the sequence
shown in the NCBI nr database for C. upsaliensis strain
RM3195. As previously mentioned, the nucleotide “start” codon
for 10 kD chaperonin gene (groES) was “GTG” (not the
commonly expected “ATG”). Similarly, the actual N-terminus
of the protein DUF465 is not consistent with the amino acid
sequence in the database and its gene (locus tag ) “CUP0317”)
Journal of Proteome Research • Vol. 6, No. 7, 2007 2545
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Table 6. Examples of Four Protein Biomarkers Detected, Extracted, and Identified from C. upsaliensis and C. helveticus Strains
That Were Shown to Have Undergone Post-Translational Removal of a Signal Peptide or Cleavage of the Polypeptide Chain

a
Signal peptide or polypeptide removed is boxed. Sequence confirmed by MS/MS is highlighted in black. Predicted MW of truncated polypeptide is compared
to the HR-ESI-MS MW of the biomarker.

also has a “TTG” “start” codon. Table 7 shows the amino acid
sequence of selected protein biomarkers analyzed in this study.
The NCBI nr amino acid sequence for 10 kD chaperonin and
2546
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DUF465 are shown (with accession numbers) including that
part of the sequence that was confirmed by MS and MS/MS.
Table 7 also aligns amino acid sequences of other selected

a
Only RM3195 has undergone genomic sequencing. Boxed residues highlight amino acid variations among species/strains. Underlined residues indicate uncertainty in the sequence due to absence of MS/MS
confirmation and discrepancies between theoretical protein MW and biomarker HR-ESI-MS MW. The NCBI GenBank accession numbers of the biomarker genes are given in parentheses next to the sequence. One
asterisk indicates the protein biomarker has a PTM. Two asterisks indicates that the gene of the protein has a “start” codon that is not confirmed by MS and MS/MS.

Table 7. Amino Acid Sequences of Protein Biomarkers of C. upsaliensis Strains RM3195, RM2092, RM4249, RM3776, RM4245 and C. helevticus RM3807
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protein biomarkers. Amino acid residue variations across
species/strains are boxed.

Discussion
Variations in Protein Biomarker MW Across Species/Strains
of C. upsaliensis and C. helveticus. As shown in Table 7,
variations in protein biomarker MW observed across species/
strains are the result of amino acid substitutions. The greater
the phylogenetic distance between species and strains, the
greater the number of amino acid variations identified among
their protein biomarkers, and the greater number of mass
“shifts” detected in MALDI-TOF-MS spectra. PTMs do not
appear to contribute to protein biomarker MW variations as
they are consistently observed across species and strains, at
least, in Campylobacter.21,22 As shown in Table 7, there are many
more amino acid subsitutions between the C. helveticus strain
and the five C. upsaliensis strains than among the C. upsaliensis
strains. Although C. helveticus is phylogenetically closer to C.
upsaliensis than to other Campylobacter species, the protein
biomarkers of RM3807 are significantly different from the
protein biomarkers of the C. upsaliensis strains in this study.
Only three (of the ten) biomarker MWs of RM3807 are common
to most (although not all) of the protein biomarker MWs of
the C. upsaliensis strains: cytochrome c family protein, 50S
ribosomal L29 protein, and DUF465. Thus, it is not surprising
that strain RM3807 is from a different (although closely related)
species than the other strains analyzed in this study. Similar
speciation of Campylobacter strains, on the basis of biomarker
MWs, was reported by our laboratory for Campylobacter,20-21
as well as sub-speciation of C. jejuni such that it was possible
to differentiate C. jejuni subsp. jejuni from C. jejuni subsp.
doylei.22
Determining the Amino Acid Sequence of a Bacterial
Protein Biomarker by CSPA. In the course of this work, the
full amino acid sequence of unknown protein biomarkers from
genomically nonsequenced bacterial strains were determined
without DNA sequencing of the biomarker gene or full de novo
MS/MS sequencing. This was accomplished by careful examination of the proteomic identifications, specifically the highest
scoring identification as well as lower scoring identifications.
Occasionally, a lower scoring identification confirmed a region
of the biomarker sequence that was not confirmed by the
highest scoring identification. Combining sequence confirmations from both the highest scoring identification and lower
scoring identifications resulted, as previously noted, in a
composite sequence that could then be confirmed by MS and
MS/MS analysis. What was surprising about this process was
that lower scoring identifications were often of proteins from
different species of Campylobacter, e.g. C. jejuni. Thus, some
of the protein biomarkers of C. upsaliensis strains RM2092,
RM4249, RM3776, and RM4245 and C. helveticus strain RM3807
had sequence regions that were more consistent with a C. jejuni
strain than with C. upsaliensis strain RM3195. Presumably, this
is due to inter-species transfer of genetic information or an
artifact of bacterial evolution.
The increasing number of bacterial genomic sequences
available in public databases make CSPA increasingly feasible.
For instance, in the determination of the sequence of the DNAbinding protein HU for C. helveticus strain RM3807, a MASCOT
search resulted in three identifications from C. jejuni, C.
upsaliensis and C. lari strains with scores of 163, 116, and 83,
respectively (see Supporting Information). However, the three
identifications covered non-overlapping regions of the HU
2548
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sequence. A composite sequence was constructed from the
three identifications. The composite sequence contained a
significant gap that was not caused by the presence of basic
residues that might generate very low MW tryptic peptides. De
novo sequencing was then used to fill in the “gap”, which was
made easier by the fact that the entire protein sequence was
not being determined but only the “gap”. Although it was
possible to use de novo sequencing at the outset of the analysis,
the task of sequence confirmation was made significantly easier
by performing CSPA prior to de novo sequencing. In addition,
CSPA may be sufficient for complete determination of the
sequence without the necessity of de novo sequencing. The
combined composite/de novo sequence was then compared
to the HR-ESI-MS MW of the protein biomarker. If concurrence was obtained, then the new composite/de novo sequence
was added to the database and confirmed by GPM analysis. In
the case of RM3807 HU, GPM analysis could not confirm the
entire composite/de novo sequence and there continued to be
a 1 Da discrepancy between the predicted MW and the HRESI-MS MW of the biomarker.
Advantages of CSPA. One clear advantage of CSPA is that,
in determining the full amino acid sequence of a protein
biomarker from a genomically non-sequenced bacterial strain,
it facilitates the reverse engineering of the biomarker gene.
Once the full amino acid sequence is known, degenerate
internal primers can be designed to sequence outward from
the gene to obtain the flanking sequences surrounding the
biomarker gene. Once these flanking sequences are obtained,
it is then possible to design primers to sequence inward to
obtain the full biomarker gene sequence. This approach is
particularly useful when the biomarker gene is from a nonsequenced emerging bacterial strain/species whose flanking
sequences may be significantly different from existing bacterial
genomes. Using primers from known genomes may result in
no amplification for the emerging strain. Thus, CSPA can
determine both the existence of the gene and facilitate a PCR
approach to determining the flanking sequences and ultimately
the full genetic sequence of the biomarker.
Errors in Start Codon of Protein Biomarker Genes in
Genome of C. upsaliensis Strain RM3195. Two of the 17
protein biomarker genes of C. upsaliensis strain RM3195 had
an incorrect start codon. As the protein biomarkers were
selected for proteomic identification on the basis of their
appearance in cell lysates analyzed by MALDI-TOF-MS, i.e.,
randomly, it is likely that there are many more start codon
errors in this genomic sequence. As there are ∼1940 genes in
the genome of C. upsaliensis strain RM3195, this may suggest
that there may be as many as ∼200 genes in the RM3195
genome with similar start codon errors. It is interesting to
observe how proteomics techniques can be used, not only to
identify PTMs, but also to correct errors in the genomic
sequencing.

Conclusions
Seventeen protein biomarkers from five strains of C. upsaliensis and one strain of C. helveticus have been detected,
extracted, and identified by proteomic techniques. Variations
in biomarker MW across species/strains were the result of
amino acid substitutions. PTMs were consistent across species/
strains of Campylobacter and thus not responsible for biomarker MW variations across species/strains. However, the
number of PTMs detected in these 17 proteins suggest that
algorithms used to “identify” protein biomarkers exclusively
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by comparison of genomically derived protein MW to MALDITOF m/z may result in mis-identification of the protein and
lowered confidence in the microorganism identification. The
rule that predicts N-terminal methionine cleavage for bacterial
proteins, as determined by the penultimate residue, was not
followed for C. upsaliensis and C. helveticus strains when the
penultimate residue was threonine. Two of the 17 protein
biomarker genes of C. upsaliensis strain RM3195 were found
to have an incorrect start codon as determined by proteomic
analysis. CSPA is a valuable technique for determining the full
amino acid sequence of a protein biomarker from a bacterial
strain whose genome has not been sequenced. As the number
of bacterial genomes increase, this technique has the potential
to identify the full amino acid sequences of many proteins
which would not be possible without full genomic sequencing.
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